Table 4 Efficiency of a 16S PCR on the patient’s management regarding sample types analyzed including the type of clinical impact
From: Impact of 16S rDNA sequencing on clinical treatment decisions: a single center retrospective study
Type of sample | 16S PCR | Clinical impact | p-value | |||
|---|---|---|---|---|---|---|
Ra | Eb | Ic | Total | |||
Cardiac valve | 173 | 6 | 7 | 0 | 13 (8%) | 0.023 |
Abscess | 71 | 7 | 3 | 3 | 13 (18%) | |
Bone sample | 80 | 4 | 1 | 1 | 6 (8%) | |
Soft tissue | 67 | 0 | 2 | 0 | 2 (3%) | |
Synovial fluid | 178 | 4 | 4 | 3 | 11 (6%) | |
CSF | 119 | 3 | 5 | 0 | 8 (7%) | |
Pleural fluid | 27 | 1 | 2 | 0 | 3 (11%) | |
Sonication fluid | 18 | 4 | 0 | 0 | 4 (22%) | |
Aqueous humour | 57 | 2 | 0 | 0 | 2 (4%) | |
Other | 16 | 0 | 0 | 0 | 0 | |
Total | 806 | 31 | 24 | 7 | 62 (8%) | – |